ReviewInvestigational new drugs2000
Development of multidrug-resistance convertors: sense or nonsense?
Review in Investigational new drugs, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 84 citations in OpenAlex.
- Phase I trial of vinorelbine and diphenylhydantoin in patients with refractory carcinoma.Investigational new drugs · 2004Trial
- Effect of valspodar on the pharmacokinetics of unbound paclitaxel.Investigational new drugs · 2003Trial
- Fenbendazole acts as a moderate microtubule destabilizing agent and causes cancer cell death by modulating multiple cellular pathways.Scientific reports · 2018Article
- Cell-penetrating peptide conjugates to enhance the antitumor effect of paclitaxel on drug-resistant lung cancer.Drug delivery · 2017Article
- Synergistic action by multi-targeting compounds produces a potent compound combination for human NSCLC both in vitro and in vivo.Cell death & disease · 2014Article
- Acid-degradable core-shell nanoparticles for reversed tamoxifen-resistance in breast cancer by silencing manganese superoxide dismutase (MnSOD).Biomaterials · 2013Article
- A target-specific oral formulation of Doxorubicin-protein nanoparticles: efficacy and safety in hepatocellular cancer.Journal of Cancer · 2013Article
- siRNA-mediated down-regulation of P-glycoprotein in a Xenograft tumor model in NOD-SCID mice.Pharmaceutical research · 2011Article
- Design of biodegradable nanoparticles for oral delivery of doxorubicin: in vivo pharmacokinetics and toxicity studies in rats.Pharmaceutical research · 2009Article
- Involvement of P-glycoprotein and multidrug resistance associated protein 1 on the transepithelial transport of a mercaptoacetamide-based histone-deacetylase inhibitor in Caco-2 cells.Biological & pharmaceutical bulletin · 2009Article
- Overcoming multidrug resistance of small-molecule therapeutics through conjugation with releasable octaarginine transporters.Proceedings of the National Academy of Sciences of the United States of America · 2008Article
- The PI3K inhibitor LY294002 blocks drug export from resistant colon carcinoma cells overexpressing MRP1.Oncogene · 2006Article
- Inhibition of efflux transporter-mediated fungicide resistance in Pyrenophora tritici-repentis by a derivative of 4'-hydroxyflavone and enhancement of fungicide activity.Applied and environmental microbiology · 2005Article
- Functional expression and localization of P-glycoprotein in the central nervous system: relevance to the pathogenesis and treatment of neurological disorders.Pharmaceutical research · 2004Review
- Role of P-glycoprotein in pharmacokinetics: clinical implications.Clinical pharmacokinetics · 2003Review
- Mechanism of 5-fluorouracil required resistance in human hepatocellular carcinoma cell line Bel(7402).World journal of gastroenterology · 2002Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This review describes the clinical relevance of the two drug transporters P-glycoprotein (Pgp) and multidrug resistance-associated protein (MRP) and the in vitro phenomenon which is referred to as multidrug resistance (MDR). The attempts to try to block these resistance mechanisms are summarized with specific attention for the intentionally designed "second generation" MDR-convertors. Potential explanations of the limited clinical success rate are given and recommendations for the design of future studies provided.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.